1	(	Cohort Profile: Prospective Cohort to Study the COVID-19 Immune Response in
2		Retail Workers in Québec, Canada (CISACOV)
3	Autho	rs: Kim Santerre <sup>1*</sup> , Mathieu Thériault <sup>1*</sup> , Nicholas Brousseau <sup>2</sup> , Samuel Rochette <sup>3</sup> ,
4	Joelle	N. Pelletier, <sup>4,5,6</sup> Caroline Gilbert, <sup>1</sup> Jean-François Masson, <sup>4,7,8,9</sup> Mariana Baz, <sup>1</sup> Denis
5	Boudre	eau, <sup>10</sup> Sylvie Trottier <sup>1</sup>
6	1.	Département de microbiologie-infectiologie et d'immunologie, Centre de
7		recherche du centre hospitalier universitaire de Québec, Université Laval,
8		Québec, QC G1V 4G2, Canada
9	2.	Biological Risks Department, Institut national de santé publique du Québec,
10		Québec, QC G1V 5B3, Canada
11	3.	SR Scientific Writing Services, Brossard, QC J4Z 3C7, Canada
12	4.	Department of Chemistry, Université de Montréal, Montréal, QC H2V 0B3,
13		Canada
14	5.	Department of Biochemistry, Université de Montréal, Montréal, QC H2V 0B3,
15		Canada
16	6.	PROTEO — The Québec Network for Research on Protein Function, Engineering,
17		and Applications, Québec, QC G1V 0A6, Canada
18	7.	Quebec center for advanced materials, Université de Montréal, Montréal, QC
19		H3C 3J7, Canada
20	8.	Regroupement québécois sur les matériaux de pointe, Université de Montréal,
21		Montréal, QC H3C 3J7, Canada

- 9. Centre interdisciplinaire de recherche sur le cerveau et l'apprentissage,
- 23 Université de Montréal, Montréal, QC H3C 3J7, Canada
- 24 10. Département de chimie et Centre d'optique, photonique et laser (COPL),
- 25 Université Laval, Québec, QC G1V 0A6, Canada
- 26 *\*Co-first authors*
- 27 Corresponding author:
- 28 Mariana Baz, PhD
- 29 E-mail : mariana.baz@crchudequebec.ulaval.ca
- 30 Tel: 418-525-4444 ext 48281
- 31 Mathieu Thériault, PhD
- 32 E-mail : mathieu.theriault@crchudequebec.ulaval.ca
- 33 Tel: 418-525-4444 ext 47992

### 34 **ABSTRACT**

*Purpose:* Retail workers are an understudied occupational group that may have been at increased risk of contracting SARS-CoV-2 during the COVID-19 pandemic. Therefore, we set up a longitudinal cohort of participants working in this sector to better document the incidence of SARS-CoV-2 infection and the immune response to infection and/or vaccination in this group.

40 Participants: A total of 304 participants were recruited between April 20, 2021 and 41 October 22, 2021. They were invited to attend three visits (each separated by ~12 weeks) 42 during which they provided blood samples and information on participant characteristics, 43 COVID-19 symptoms, and vaccination. An extension phase of two additional visits was carried out between March 15<sup>th</sup>, 2022 and October 3<sup>rd</sup>, 2022 to document the impact of 44 45 the Omicron variant among the 198 participants who were still eligible for recruitment. 46 Participants were aged 18 to 75 and worked in grocery stores, hardware stores, bars or restaurants within the Québec City metropolitan area (Canada). Findings to date: This 47 48 article describes participants' demographic, socioeconomic, behavioral, clinical and 49 occupational characteristics, and their COVID-19 symptoms (where applicable). It also 50 describes SARS-CoV-2 vaccination status and any SARS-CoV-2 diagnostic test (i.e., PCR or rapid antigen) performed from the beginning of the pandemic until the last visit. 51

52 *Future plans:* The incidence of SARS-CoV-2 infections will be assessed. The immune 53 response (innate and acquired) to SARS-CoV-2 infection or vaccination will be studied

using a variety of techniques, including reference and experimental enzyme-linked immunosorbent assays, microneutralization assays with live viruses, experimental pseudoneutralization with an angiotensin-converting enzyme 2-spike assay, peripheral blood mononuclear cells and neutrophil stimulation, and a proliferation assay based on carboxyfluorescein diacetate succinimidyl ester.

59 *Registration:* Not applicable.

### 60 Strengths and limitations

This cohort offers a comprehensive dataset to study the immune response to
 SARS-CoV-2 infection or vaccination (alone), or hybrid immunity, as participants
 provided information on a wide range of demographic, socioeconomic,
 behavioral, clinical, and occupational variables. However, the low proportion of
 racial minorities (i.e., 3.0%) limits the use of this cohort to study racial
 determinants of immunity to SARS-CoV-2.

- This cohort focuses on workers in the food and retail service sector, an
   understudied population at high risk of occupational exposure to infectious
   agents.
- This study covered seven pandemic waves and thus captured a large number of
   confirmed infections from different variants.
- Sample collection was initiated immediately prior to COVID-19 vaccine availability
   for this population and thus captured successive vaccination campaigns over 17
   months.

75	•	In keeping with the study design, none of the participants had severe COVID-19
76		disease requiring hospitalization at baseline, and none of the COVID-19 illnesses
77		that occurred during the study required hospitalization; this cohort may not,
78		therefore, be used to study the immune response leading to severe health
79		outcomes, but is appropriate to study the immune response to mild SARS-CoV-2
80		infections.
81	•	Nearly 1300 blood samples were collected; furthermore, only 13 out of 304 (4.3%)
82		participants withdrew before attending all three initial visits, and 4 out of 198
83		(2.0%) participants who remained eligible in the extension phase withdrew before
84		attending the fifth visit. A series of at least 5 blood samples drawn over 48 weeks
85		is therefore available for most participants.

### 86 **INTRODUCTION**

During the SARS-CoV-2 pandemic, workers with client-facing duties were considered to be at greater risk of infection than those who worked remotely.<sup>1-3</sup> Although most studies have focused on healthcare workers (HCW),<sup>4 5</sup> many non-HCWs were also considered to be at risk due to their occupational exposure.<sup>67</sup>

Workers in the food and retail industry are an understudied occupational group that 91 92 may have been at greater risk of contracting SARS-CoV-2. These workers often have below-average incomes, face precarious employment conditions and lack benefit 93 94 packages to cover health-related absenteeism. At the beginning of the pandemic, these 95 workers often lacked the training and the access to protective equipment used by HCWs to reduce exposure.<sup>8</sup> However, risk is likely to vary from one sector to another. For 96 97 example, grocery stores were considered an essential service and therefore remained 98 open throughout the pandemic, with public health measures (e.g., mask wearing) being enforced and generally well respected. In contrast, restaurants and bars were 99 100 intermittently opened and closed by health authorities over the same period, and public 101 health measures were more difficult to enforce due to the intrinsically social nature of these businesses and their main purpose — the consumption of food and drink — that 102 precluded continuous mask wearing. 103

104 Compelling evidence now confirms that the risk of occupational exposure is high for 105 these workers. In a serological survey conducted in New York City prior to the approval of 106 the first COVID-19 vaccine, the seroprevalence of anti-spike antibodies was higher among

107 grocery store and restaurant workers than in most subgroups of HCWs.<sup>1</sup> In another 108 serosurvey conducted in Switzerland, kitchen staff and grocery store workers exhibited 109 an above-average seroprevalence compared to other essential workers.<sup>9</sup> In the 110 Netherlands, individuals working in the hospitality sector were more likely to have a 111 positive PCR test result than those working in non-close-contact occupations.<sup>10</sup> In Japan, 112 restaurants and bars were the second most common setting of SARS-CoV-2 outbreaks 113 after healthcare facilities.<sup>7</sup><sup>11</sup>

114 To date, no thorough investigation of SARS-CoV-2 exposure has been conducted among Canadian workers in grocery stores, hardware stores, bars or restaurants.<sup>12 13</sup> Such 115 116 an investigation could help better prepare health authorities when implementing future 117 measures, including the designation of priority groups for vaccination, and mandatory 118 lockdowns in these sectors. Accordingly, we set up a longitudinal cohort that investigated 119 the incidence of COVID-19 and the humoral and cellular immunity (innate and acquired) 120 to SARS-CoV-2 in these workers. This article describes the experimental design of the project and the cohort of participants. 121

### 122 COHORT DESCRIPTION

#### 123 Participants and setting

Eligibility criteria included the following: (1) providing informed consent; (2) age  $\geq$ 18 years; (3) working either on a full-time or part-time basis in a grocery store, hardware store, bar or restaurant located in the administrative regions of Capitale-Nationale and Chaudière-Appalaches that include and surround the area of Québec City, Canada; (4) having a public-facing role in daily work-related activities; (5) having worked  $\geq$ 20 full days between February 1<sup>st</sup>, 2020 and the first visit; and (6) having no history of hospitalization due to COVID-19.

Participants were recruited using a variety of strategies: 1) an online recruitment campaign conducted by a student-run communication agency; 2) email invitations to members of partner union organizations - *Confédération des syndicats nationaux* (CSN) and to sectoral organizations of hardware store workers - *Association Québécoise de la quincaillerie et des matériaux de construction* (AQMAT); and 3) email information to all students and employees at *Université Laval* and the *Centre Hospitalier Universitaire de Québ*ec in order to publicize the study.

138 Design and procedures

The study was initially designed as a prospective cohort study with three sampling visits, each separated by 12±2 weeks, between April 20<sup>th</sup>, 2021 and October 3<sup>rd</sup>, 2022. In response to the emergence of Omicron, an extension of two additional visits was proposed to the participants who were still eligible for recruitment. An additional COVID-

143 19 visit (VCoV) was also planned shortly after the occurrence of any SARS-CoV-2 infection
144 during the study period (Figure 1).

At the first visit ("V1"), participants signed an informed consent form and were then interviewed by trained nurses to obtain information on demographic, socioeconomic, behavioral, clinical and occupational variables (Table 1). The questionnaires were adapted from those suggested by our funding body, the COVID Immunity Task Force (CITF).<sup>14</sup> At or after the third visit ("V3"), eligible participants received information about the extension of the study and signed a new informed consent if they were interested in participating.

At the second ("V2"), third ("V3"), fourth ("V4") and fifth visits ("V5"), participants completed an abridged version of the V1 questionnaire that focused the COVID-19 vaccines that they received and SARS-CoV-2 symptoms, diagnosis, exposure and associated risk factors (Table 1). Blood was drawn to study humoral immunity (i.e., at V1 to V5) and cellular immunity (i.e., at V1, V3, and V5) to SARS-CoV-2. Additional PCR tests were carried out at V4 and V5 to detect asymptomatic carriers.

157 The VCoV visits took place at a median time of 15 days (10 to 42 days) after the onset 158 of symptoms. Blood was drawn to study humoral and cellular immunity and a 159 questionnaire focusing exclusively on SARS-CoV-2 diagnosis and symptoms was 160 completed at that visit.

#### 161 Study exposures and follow-up

162 The two main exposures of the study were SARS-CoV-2 infection, defined as a 163 positive test result for SARS-CoV-2 (PCR or antigen detection), and participants'

164	vaccination status. Participants were asked about possible or confirmed SARS-CoV-2
165	infection (i.e., symptoms, diagnostic test, test date and test result) and their SARS-CoV-2
166	vaccination history (i.e., number of doses, date of vaccination, type of vaccine) since the
167	beginning of the pandemic at V1, and since the last visit (at V2 to V5). Positive SARS-CoV-
168	2 test results were therefore captured from the beginning of the pandemic until the
169	earliest among the last visit, withdrawal from the study, or loss of eligibility.
170	Study outcome
171	The primary outcomes were vaccine- and infection-induced immunity. We also
172	explored the humoral immunity, using different techniques and antigens, and the cellular
173	immunity (innate and acquired).
174	Confidentiality and data storage
175	This study was approved by the « Comité d'éthique de la recherche du CHU de Québec
176	- Université Laval » (registration number 2021-5744). A unique, anonymized identifier
177	was assigned to each participant and used to store the data and the samples. The samples
178	will be stored for up to 10 years, and the data for at least 15 years.
179	Patient and public involvement statement
180	No public stakeholders were involved in establishing and designing this cohort.
181	Participant characteristics
182	Overall, 304 individuals were initially recruited to attend the three first visits from
183	April 20 <sup>th</sup> , 2021 to May 9 <sup>th</sup> , 2022. The cohort included 149 (49.0%) restaurant/bar

workers, 112 (36.8%) grocery store workers, and 43 (14.1%) hardware store workers.
With the emergence of Omicron, 198 participants who at the time of ethic approval were
still within the recruiting window, were included for two additional visits (12±4 weeks
apart) between March 15<sup>th</sup>, 2022 and October 3<sup>rd</sup>, 2022. Only 13 out of 304 (4.3%)
withdrew before V3, and only 4 more out of 198 (2.0%) withdrew at V5, resulting in a
series of at least 5 blood samples drawn over 48 weeks for most participants.

190 On average, participants were aged 41.3 years in the overall cohort (Table 2). 191 Specifically, restaurants/bar workers were on average 37.2 years old, grocery store 192 workers 44.2 and hardware store workers 48.2. Female participants represented 57.9% 193 of the cohort. Overall, 96.7% self-identified as White, 1.6% as Asian, 1.0% as Latino 194 American, and 0.7% as Black. The low proportion of racial minorities (i.e., 3.3%) is 195 consistent with the size of the visible minority population in the Québec City metropolitan area (i.e., 4.9% according to census).<sup>15</sup> Levels of education varied: 39.4% reported having 196 197 a high school diploma or vocational certificate, 33.2% a higher education certificate and 22.7% at least a university degree. In total, 76.0% of participants resided in the Capitale-198 199 Nationale administrative region, the remainder residing in the Chaudière-Appalaches 200 administrative region (Table 3). Most (i.e., 62.2%) lived alone or with one other person, 201 23.0% lived with children (<18 years), 15.5% with HCWs and 7.6% with teachers or 202 kindergarten workers. These distributions were similar within each occupational group.

According to body mass index (BMI), 41.1% of the participants had a healthy weight (i.e., BMI=18.5 to 24.9 kg/m<sup>2</sup>), 27.0% were overweight (BMI=25.0 to 29.9 kg/m<sup>2</sup>) and

30.6% were obese (BMI ≥30 kg/m²) (Table 4). Only 1.3% were considered underweight
(BMI <18.5 kg/m²). Cigarette (i.e., tobacco) use was reported by 17.4% of the participants</li>
and e-cigarette use by 7.9%. About half (i.e., 47.7%) of participants reported having at
least one comorbidity. Hardware store workers had more comorbidities, probably
because they were slightly older (on average). Overall, 17.1% reported usually receiving
an annual influenza vaccine (13.8% in the year prior to the first visit).

211 Approximately half (i.e., 53.6%) of the participants reported working on average 212 more than 30 hours per week (Table 5). Most (88.8%) had attended at least one gathering 213 of 10 or more persons during the study period, and 40.8% reported attending more than 214 10 such gatherings. The predominant mode of transportation was by car (88%), followed 215 by bus (12.8%) and walking (9.2%). Traveling outside the province of Québec was reported 216 by 47.0% of the participants, with 25.7% travelling within Canada, 14.8% to the United 217 States, and 27.6% elsewhere. The distribution of participants in each occupational group 218 was similar for the workplace region, mode of transportation and travelling, but differed 219 for the weekly hours worked and the number of gatherings attended.

Overall, 98.7% of the participants reported wearing a mask at work, indicating excellent adherence to this measure (Table 6). Other measures, such as handwashing (98.4%), distancing (70.1%) and the use of Plexiglas dividers (77.3%) were also frequent. The use of gloves (6.9%) and face-shields (10.5%), which were not extensively promoted by the regional public health authorities, were less frequent. Outside work, all participants reported wearing a mask in public (100.0%); most avoided usual salutations

(85.2%), practiced social distancing (84.2%) and avoided contact with vulnerable persons
(83.6%) and crowded places (76.6%). Most participants reported washing their hands
when dirty (96.7%), after using the bathroom (97.7%), when arriving at (92.1%) and
leaving the workplace (71.7%), before eating (87.8%) and after handling trash (79.6%). In
general, adherence to these measures was consistently lower among restaurant and bar
workers, possibly because of the nature of their work or their younger age (on average).

#### 232 FINDINGS TO DATE

#### 233 SARS-CoV-2 infection

234 Overall, 168 positive tests were reported in 121 participants throughout the study 235 period (Table 7). Of these tests, 117 were the first to yield a positive result as reported by 236 the participants; 40 (performed by 37 participants) were additional tests with 32 237 considered follow-up tests (<90 days since previous test) and 8 detecting a second or third 238 infection (>90 days since previous test). The remaining 11 (including four first-ever 239 positives) were PCR tests performed as per protocol at V4 and V5 among asymptomatic 240 or pre-symptomatic individuals. In addition, 29 participants reported 31 suspected 241 COVID-19 infections based on their symptoms, although not confirmed by a PCR or 242 antigen detection test.

243 SARS-CoV-2-related symptoms

Among the 117 participants with a first confirmed SARS-CoV-2 infection, 94.9% reported  $\geq$ 1 symptom at the time of testing (Table 8). Each individual symptom was experienced by  $\geq$ 47.9% of participants, except for diarrhea (13.7%) and loss of smell or

taste (22.2%), a pattern consistent with prior studies.<sup>16-18</sup> These distributions were similar
within each occupational group.

249 Vaccination for SARS-CoV-2

250 The participants were vaccinated according to local government recommendations 251 with the vaccines approved by Canadian health authorities. The COVID-19 vaccines 252 available were monovalent Comirnaty (Pfizer-BioNTech), Spikevax (Moderna) and 253 Vaxzevria (AstraZeneca), which each required two doses to complete the primary series. 254 Hardware store workers were the most highly vaccinated occupational group, 100% of 255 them having received two doses by February 2022 (Figure 2). By the end of the study (i.e., last visit between May 10<sup>th</sup>, 2022 and October 3<sup>rd</sup>, 2022), nearly 70% of all participants 256 257 had received at least one booster dose.

At the time of testing positive, 17.9% of the participants had received no vaccine dose, 0.9% had received a single dose of vaccine, 38.4% had received two, 39.3% had received three, and 3.4% had received four (Table 9). In participants who tested positive and had received at least two vaccine doses, all infections occurred after the 4<sup>th</sup> wave, when the Omicron variant was predominant.

263 Blood sample bank to study infection-induced, vaccine-induced, and hybrid immunity

Overall, 1299 blood samples were collected, including 304 (23.4%) at V1, 297 (22.9%) at V2, 291 (22.4%) at V3, 198 (15.2%) at V4, 194 (15.0%) at V5, and 15 (1.2%) at additional visits (i.e., VCoV). In total, 69.2% of the blood samples were drawn from vaccinated participants with no known history of SARS-CoV-2 infection, 23.1% from vaccinated and

previously infected participants, 6.9% from unvaccinated participants with no known
history of SARS-CoV-2 infection, and 11 (0.8%) from previously infected and unvaccinated
participants (Table 10).

## 271 STRENGTHS AND LIMITATIONS

272 We set up a cohort of 304 participants to conduct a longitudinal study of COVID-19 273 immunity among food and retail workers who lived and worked within the greater 274 Québec City metropolitan region. The participants provided information on a wide range 275 of demographic, socioeconomic, behavioral, clinical and occupational variables. The study 276 covered seven waves of COVID-19 infection, including those dominated by the Alpha, 277 Delta, and Omicron variants, thus capturing a relatively large number of epidemiological 278 periods and infections. In addition, the blood samples were collected at each scheduled 279 visit regardless of participants' infection or vaccination history, thus enabling the study of 280 infection-induced, vaccine-induced and hybrid immunity in this extensively characterized 281 cohort. Moreover, few participants withdrew from the study before the end of the initial 282 (i.e., V1-V3) and extension phases (i.e., V4-V5), resulting in complete series of at least 5 283 samples for most participants.

A total of 117 first (ever) COVID-19 infections were reported, and most occurred between December 5<sup>th</sup>, 2021 and October 3<sup>rd</sup>, 2022, consistent with the emergence of the highly contagious Omicron variant. In the present study, vaccine coverage was high: by the time Omicron had emerged, nearly 95% of the participants had already received two vaccine doses (primary series). This high rate of vaccination may be because retail

workers considered themselves at higher risk of SARS-CoV-2 exposure than the general
population and were thus more willing to get vaccinated and reduce their risk of infection.

291 Some limitations must be considered when interpreting our results. Per the study 292 design, none of the participants had previously experienced a severe COVID-19 illness 293 that required hospitalization. Therefore, the cohort may not be used to study the immune response that leads to severe health outcomes, but is appropriate to study the immune 294 295 response to mild COVID-19 illness. Furthermore, our study was not designed to infer a 296 causal relationship between a worker's occupational sector and the risk of SARS-CoV-2 297 infection, such that confounders probably explain part of the differences among 298 occupational groups. For example, relative to hardware store workers, grocery store 299 workers were younger (i.e., mean age: 44.2 vs. 48.2 years), included more overweight or 300 obese participants (i.e., 72.3% vs. 46.5%), and lived in more crowded households (i.e., 301 proportion with  $\geq$ 3 residents: 49.1% vs. 25.6%), which may have predisposed them to 302 infection. Another limitation is that the cohort may have been subject to a sampling bias 303 as there may be less vaccine hesitancy among people willing to participate in a scientific 304 study. Hence, the study participants may not be representative of the overall population of workers in these sectors. This is suggested by the 5% to 7% higher vaccination coverage 305 306 for the second dose as of fall 2021 compared to the general population of the province of 307 Québec.

308 The low proportion of racial minorities (i.e., 3.0%) also limits the use of this cohort to 309 study racial determinants of immunity to SARS-CoV-2. In addition, participant responses

310 may have been affected by a memory bias, particularly for those whose last infection 311 occurred months before V1. Moreover, few samples were drawn from unvaccinated and 312 previously infected participants, so that the cohort may be of limited use to study 313 immunity induced by infection alone. The high vaccination coverage also made it 314 impossible to assess the impact of vaccination on the risk of infection, since, at any given 315 time, most participants had been vaccinated. Lastly, our study may have underestimated the incidence of SARS-CoV-2 infection since most infections occurred during the Omicron 316 317 wave, when access to PCR-based screening was limited in Québec (and only less sensitive 318 antigen detection tests were available). The serology data of these samples will shed light 319 on this question.

### 320 COLLABORATION

More detailed, participant-level information is publicly available on an online platform developed by Maelstrom Research.<sup>19</sup> Researchers with other enquiries or collaboration proposals may contact Sylvie Trottier — the principal investigator in charge of setting up the cohort — at <u>sylvie.trottier@crchudequebec.ulaval.ca</u>. Data on participants' immune responses to SARS-CoV-2 infection and vaccination will be shared through peer-reviewed publications.

Funding: This project is being supported by funding from the Public Health Agency of
 Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity
 Task Force (grant number: 2021-HQ-000134).

330 **Competing interests statement:** Nothing to declare.

- **Data sharing statement:** All participant-level information is publicly available on an online
- 332 platform developed by Maelstrom Research.
- 333 Author contributions: The co-principal investigators of the study were DB and ST, who
- 334 conceived the study and led the proposal. Protocol design and development team: J.N.P.,
- 335 C.G., J.-F.M., M.B., D.B., and S.T. K.S. constructed the data base, coordinated the study
- and contributed to the data analysis. M.T. did the maintenance and the development of
- the data base, the cleaning of the data and contributed to data analysis. N.B. oversaw
- the data analysis. S.R. participated to data analysis and wrote the first draft of the
- manuscript. All authors critically reviewed and approved the final manuscript.
- 340 Acknowledgements: The authors thank the participants and all the staff involved in
- 341 planning and preparation of this study. David Simonyan helped with statistical analysis. A
- 342 special thank you to our partners: CSN Federation of Commerce and AQMAT.
- 343 ORCID iDs
- 344 Sylvie Trottier <u>https://orcid.org/0000-0002-3986-5146</u>
- 345 Denis Boudreau https://orcid.org/ 0000-0001-5152-2464
- 346 Caroline Gilbert <u>https://orcid.org/0000-0003-2722-1180</u>
- 347 Jean-Francois Masson https://orcid.org/0000-0002-0101-0468
- 348 Mariana Baz <u>https://orcid.org/0000-0002-1230-0735</u>
- 349 Joelle Pelletier https://orcid.org/0000-0002-2934-6940
- 350 Mathieu Thériault <u>https://orcid.org/0000-0002-7293-7623</u>

## 351 **REFERENCES**

- Pathela P, Crawley A, Weiss D, et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the United States: Findings From New York City, 13 May to 21 July 2020. *J Infect Dis* 2021;224(2):196-206. doi: 10.1093/infdis/jiab200
- Feehan AK, Velasco C, Fort D, et al. Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA. *Emerg Infect Dis* 2021;27(1) doi: 10.3201/eid2701.203808 [published Online First: 20201110]
- 3. Sim MR. The COVID-19 pandemic: major risks to healthcare and other workers on the
  front line. *Occup Environ Med* 2020;77(5):281-82. doi: 10.1136/oemed-2020106567 [published Online First: 20200401]
- 4. Gomez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in Health-Care Workers: A
  Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical
  Characteristics, and Outcomes. *Am J Epidemiol* 2021;190(1):161-75. doi:
  10.1093/aje/kwaa191
- 5. Gholami M, Fawad I, Shadan S, et al. COVID-19 and healthcare workers: A systematic
  review and meta-analysis. *Int J Infect Dis* 2021;104:335-46. doi:
  10.1016/j.ijid.2021.01.013 [published Online First: 20210111]
- 369 6. Boucher E, Cao C, D'Mello S, et al. Occupation and SARS-CoV-2 seroprevalence
  370 studies: a systematic review. *BMJ Open* 2023;13(2):e063771. doi:
  371 10.1136/bmjopen-2022-063771 [published Online First: 20230228]
- 7. Vachon MS, Demmer RT, Yendell S, et al. SARS-CoV-2 Seroprevalence Survey in Grocery Store Workers-Minnesota, 2020-2021. *Int J Environ Res Public Health* 2022;19(6) doi: 10.3390/ijerph19063501 [published Online First: 20220316]
- 8. Parks CA, Nugent NB, Fleischhacker SE, et al. Food System Workers are the
  Unexpected but Under Protected COVID Heroes. *J Nutr* 2020;150(8):2006-08. doi:
  10.1093/jn/nxaa173
- 9. Stringhini S, Zaballa ME, Pullen N, et al. Large variation in anti-SARS-CoV-2 antibody
  prevalence among essential workers in Geneva, Switzerland. *Nat Commun*2021;12(1):3455. doi: 10.1038/s41467-021-23796-4 [published Online First:
  20210608]
- 10. de Gier B, de Oliveira Bressane Lima P, van Gaalen RD, et al. Occupation- and ageassociated risk of SARS-CoV-2 test positivity, the Netherlands, June to October
  2020. *Euro Surveill* 2020;25(50) doi: 10.2807/1560-7917.ES.2020.25.50.2001884
- 11. Furuse Y, Sando E, Tsuchiya N, et al. Clusters of Coronavirus Disease in Communities,
  Japan, January-April 2020. *Emerg Infect Dis* 2020;26(9) doi:
  10.3201/eid2609.202272 [published Online First: 20200610]
- 12. Decarie Y, Michaud PC. Counting the Dead: COVID-19 and Mortality in Quebec and British Columbia During the First Wave. *Can Stud Popul* 2021;48(2-3):139-64. doi: 10.1007/s42650-021-00053-z [published Online First: 20210917]
- 391 13. Shim E. Regional Variability in COVID-19 Case Fatality Rate in Canada, February 392 December 2020. Int J Environ Res Public Health 2021;18(4) doi: 393 10.3390/ijerph18041839 [published Online First: 20210214]

394	14. COVID-19 Immunity Task Force standardized core survey data elements [Availa	able
395	from: https://www.covid19immunitytaskforce.ca/covid-19-immunity-task-for	rce-
396	releases-standardized-core-survey-data-elements/ accessed February 15th, 20	023
397	2023.	

- 15. 2016 [Available 398 Census profile, census. Ouébec City from: https://www12.statcan.gc.ca/census-recensement/2016/dp-399 400 pd/prof/details/page.cfm?Lang=E&Geo1=CSD&Code1=2423027&Geo2=CD&C 401 ode2=2423&Data=Count&SearchText=quebec&SearchType=Begins&SearchPR =01&B1=All&TABID=1 accessed February 16th, 2023. 402
- 403 16. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A meta404 analysis. *J Med Virol* 2020;92(10):1902-14. doi: 10.1002/jmv.25884 [published
  405 Online First: 20200624]
- 406 17. Burke RM, Killerby ME, Newton S, et al. Symptom Profiles of a Convenience Sample
   407 of Patients with COVID-19 United States, January-April 2020. MMWR Morb
   408 Mortal Wkly Rep 2020;69(28):904-08. doi: 10.15585/mmwr.mm6928a2 [published
   409 Online First: 20200717]
- 410 18. Government C. COVID-19 signs, symptoms and severity of disease: A clinician guide.
   411 [Available from: <u>https://www.canada.ca/en/public-health/services/diseases/2019-</u>
   412 novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html.
- 413 19. Boudreau DT, Sylvie; Masson, Jean-François; Baz Etchebarne, Mariana; Gilbert,
  414 Caroline; Pelletier, Joëlle;. CISACOV investigators. Cellular Immunity and
  415 Seroprevalence of Antibodies against SARS-CoV-2: Characterisation of Three
  416 Populations of Food Workers. , 2021-2022.
- 20. Canada Go. COVID-19 vaccination in Canada: Government of Canada; 2023 [updated
  2023-03-03. Available from: <u>https://health-infobase.canada.ca/covid-</u>
  19/vaccination-coverage/.

# **TABLES AND FIGURES**

# 422 Table 1. Participant visits

	Visit 1 N=304	Visit 2 N=297	Visit N=291	Visit 4 N=198	Visit 5 N=194	COVID-19 visit (VCoV) N=15
Retention	100%	98%	96%	100%	98%	-
Eligibility assessment	Х			Х		
Consent form	Х			Х		
Participant characteristics Demographic data Household data Clinical data Occupational data	X X X X	х	х	x	х	Х
<b>Retrospective questionnaire form</b> COVID-19 positive tests & symptoms Vaccine status	X X	X X	X X	X X	X X	x x
<b>Cross-section interventions</b> Humoral immunity blood samples Cellular immunity blood samples COVID-19 PCR test at visit	x x	х	x x	x x	X X X	X X

## 424 Table 2. Detailed demographics of study participants at the first visit

	Overall study population		Restaur wor	Restaurant/bar workers		Grocery store workers		re store kers
	Total (N=304)	COVID-19 <sup>1</sup> (N=117)	Total (N=149)	COVID-19 <sup>1</sup> (N=62)	Total (N=112)	COVID-19 <sup>1</sup> (N=42)	Total (N=43)	COVID-19 <sup>1</sup> (N=13)
Age (years), Mean±SD Age groups, N (%)	41.3 ± 15.9	<b>39.6</b> ± 14.6	37.2 ± 14.8	36.2 ± 14.3	44.2 ± 15.3	42.4 ± 14.1	48.2 ± 17.3	46.5 ± 14.6
18-59	257 (84.5%)	106 (90.6%)	135 (90.6%)	57 (91.9%)	93 (83.0%)	37 (88.1%)	29 (67.4%)	12 (92.3%)
60-75	47 (15.5%)	11 (9.4%)	14 (9.4%)	5 (8.1%)	19 (17.0%)	5 (11.9%)	14 (32.6%)	1 (7.7%)
Sex, N (%)								
Female	176 (57.9%)	72 (61.5%)	95 (63.8%)	39 (62.9%)	57 (50.9%)	25 (59.5%)	24 (55.8%)	8 (61.5%)
Male	128 (42.1%)	45 (38.5%)	54 (36.2%)	23 (37.1%)	55 (49.1%)	17 (40.5%)	19 (44.2%)	5 (38.5%)
Race/ethnicity, <sup>2</sup> N (%)								
White	294 (96.7%)	114 (97.4%)	142 (95.3%)	61 (98.4%)	109 (97.3%)	40 (95.2%)	43 (100.0%)	13 (100.0%)
Asian	5 (1.6%)	0 (0.0%)	4 (2.7%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Black	2 (0.7%)	2 (1.7%)	0 (0.0%)	0 (0.0%)	2 (1.8%)	2 (4.8%)	0 (0.0%)	0 (0.0%)
Latino American	3 (1.0%)	1 (0.9%)	3 (2.0%)	1 (1.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Educational attainment, N (%)								
Less than high school	14 (4.6%)	3 (2.6%)	4 (2.7%)	2 (3.2%)	9 (8.0%)	0 (0.0%)	1 (2.3%)	1 (7.7%)
High school	79 (26.0%)	27 (23.1%)	42 (28.2%)	14 (22.6%)	23 (20.5%)	7 (16.7%)	14 (32.6%)	6 (46.2%)
Professional certificate	<b>41</b> (13.5%)	13 (11.1%)	19 (12.8%)	6 (9.7%)	16 (14.3%)	6 (14.3%)	6 (14.0%)	1 (7.7%)
CEGEP and college certificate	101 (33.2%)	45 (38.5%)	51 (34.2%)	26 (41.9%)	35 (31.3%)	14 (33.3%)	15 (34.9%)	5 (38.5%)
University baccalaureate	54 (17.8%)	22 (18.8%)	28 (18.8%)	12 (19.4%)	21 (18.8%)	10 (23.8%)	5 (11.6%)	0 (0.0%)
Graduate studies	15 (4.9%)	7 (6.0%)	5 (3.4%)	2 (3.2%)	8 (7.1%)	5 (11.9%)	2 (4.7%)	0 (0.0%)

425 Abbreviations: CEGEP = General and professional teaching college

426 Notes:

427 1. Subset of participants who contracted COVID-19 at least once during the study period.

428 2. Self-reported by study participants

## 429 Table 3. Household characteristics of the participants at the first visit

	Overall study population		Restau wor	Restaurant/bar workers		ry store kers	Hardware store workers	
	Total	COVID-19 <sup>1</sup>	Total	COVID-19 <sup>1</sup>	Total	COVID-19 <sup>1</sup>	Total	COVID-19 <sup>1</sup>
	(N=304)	(N=117)	(N=149)	(N=62)	(N=112)	(N=42)	(N=43)	(N=13)
Region, N (%)								
Capitale-Nationale	231 (76,0%)	91 (77,8%)	112 (75,2%)	45 (72,6%)	86 (76,8%)	35 (83,3%)	33 (76,7%)	11 (84,6%)
Chaudière-Appalaches	73 (24,0%)	26 (22,2%)	37 (24,8%)	17 (27,4%)	26 (23,2%)	7 (16,7%)	10 (23,3%)	2 (15,4%)
Household size, N (%)								
1-2 residents	189 (62,2%)	76 (65,0%)	100 (67,1%)	48 (77,4%)	57 (50,9%)	19 (45,2%)	32 (74,4%)	9 (69,2%)
3-4 residents	93 (30,6%)	32 (27,4%)	36 (24,2%)	10 (16,1%)	48 (42,9%)	19 (45,2%)	9 (20,9%)	3 (23,1%)
≥5 residents	22 (7,2%)	9 (7,7%)	13 (8,7%)	4 (6,5%)	7 (6,3%)	4 (9,5%)	2 (4,7%)	1 (7,7%)
Co-residents, N (%)								
Underage (<18)	70 (23,0%)	29 (24,8%)	35 (23,5%)	12 (19,4%)	29 (25,9%)	14 (33,3%)	6 (14,0%)	3 (23,1%)
Healthcare worker	47 (15,5%)	17 (14,5%)	23 (15,4%)	9 (14,5%)	18 (16,1%)	5 (11,9%)	6 (14,0%)	3 (23,1%)
Kindergarden worker	10 (3,3%)	3 (2,6%)	5 (3,4%)	1 (1,6%)	5 (4,5%)	2 (4,8%)	0 (0,0%)	0 (0,0%)
Teacher	13 (4,3%)	7 (6,0%)	9 (6,0%)	4 (6,5%)	4 (3,6%)	3 (7,1%)	0 (0,0%)	0 (0,0%)
Household bedroom, N (%)								
0-2	158 (52,0%)	66 (56,4%)	90 (60,4%)	41 (66,1%)	49 (43,8%)	19 (45,2%)	19 (44,2%)	6 (46,2%)
≥3	146 (48,0%)	51 (43,6%)	59 (39,6%)	21 (33,9%)	63 (56,3%)	23 (54,8%)	24 (55,8%)	7 (53,8%)

430 Notes:

431 1. Subset of participants who contracted COVID-19 had least once during the study period.

432

## 434 **Table 4. Clinical characteristics of study participants at the first visit**

	Overall study population		Restau wor	Restaurant/bar workers		ry store rkers	Hardware store workers	
	Total (N=304)	COVID-19 <sup>1</sup> (N=117)	Total (N=149)	COVID-19 <sup>1</sup> (N=62)	Total (N=112)	COVID-19 <sup>1</sup> (N=42)	Total (N=43)	COVID-19 <sup>1</sup> (N=13)
BMI scores, Mean±SD BMI categories N (%)	27,3 ± 6,1	<b>27,5</b> ± 6,4	27,0 ± 6,9	26,83 ± 6,7	28,1 ± 5,3	<b>27,94</b> ± 5,2	26,3 ± 5,3	27,51 ± 6,6
<18.5 (underweight)	4 (1.3%)	1 (0.9%)	2 (1 3%)	1 (1.6%)	2 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
18 5-24 9 (healthy weight)	<b>125</b> (41 1%)	49 (41 9%)	<b>73</b> (49.0%)	30 (48.4%)	<b>2</b> (1,0%) <b>29</b> (25.9%)	<b>13</b> (31.0%)	<b>23</b> (53 5%)	6 (46 2%)
25 0-29 9 (overweight)	82 (27.0%)	<b>23</b> (19.7%)	31 (20.8%)	10 (16,1%)	39 (34.8%)	9 (21.4%)	12 (27 9%)	<b>4</b> (30.8%)
≥30 (obesity)	93 (30,6%)	44 (37,6%)	43 (28,9%)	21 (33,9%)	42 (37,5%)	20 (47,6%)	8 (18,6%)	3 (23,1%)
Smoking, N (%)								
Cigarette user	53 (17,4%)	22 (18,8%)	33 (22,1%)	14 (22,6%)	16 (14,3%)	6 (14,3%)	4 (9,3%)	2 (15,4%)
E-cigarette user	24 (7,9%)	8 (6,8%)	20 (13,4%)	6 (9,7%)	3 (2,7%)	2 (4,8%)	1 (2,3%)	0 (0,0%)
Comorbidities, <sup>2</sup> N (%)								
Hypertension	39 (12,8%)	11 (9,4%)	13 (8,7%)	4 (6,5%)	18 (16,1%)	6 (14,3%)	8 (18,6%)	1 (7,7%)
Chronic pulmonary disease	33 (10,9%)	17 (14,5%)	13 (8,7%)	6 (9,7%)	14 (12,5%)	10 (23,8%)	6 (14,0%)	1 (7,7%)
Diabetes mellitus	18 (5,9%)	5 (4,3%)	4 (2,7%)	1 (1,6%)	11 (9,8%)	3 (7,1%)	3 (7,0%)	1 (7,7%)
Hypothyroidism	16 (5,3%)	4 (3,4%)	6 (4,0%)	2 (3,2%)	6 (5,4%)	1 (2,4%)	5 (11,6%)	1 (7,7%)
Cancer	10 (3,3%)	3 (2,6%)	4 (2,7%)	1 (1,6%)	5 (4,5%)	2 (4,8%)	1 (2,3%)	0 (0,0%)
Cardiovascular disease	8 (2,6%)	2 (1,7%)	2 (1,3%)	0 (0,0%)	3 (2,7%)	1 (2,4%)	3 (7,0%)	1 (7,7%)
Immune deficiency	7 (2,3%)	5 (4,3%)	3 (2,0%)	3 (4,8%)	1 (0,9%)	0 (0,0%)	3 (7,0%)	2 (15,4%)
Chronic neurological disorder	6 (2,0%)	1 (0,9%)	2 (1,3%)	1 (1,6%)	3 (2,7%)	0 (0,0%)	1 (2,3%)	0 (0,0%)
Liver disease	2 (0,7%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	1 (0,9%)	0 (0,0%)	1 (2,3%)	0 (0,0%)
Blood disorder	1 (0,3%)	1 (0,9%)	1 (0,7%)	1 (1,6%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)
Obesity <sup>3</sup>	1 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Kidney disease	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)	0 (0,0%)
Influenza vaccination, N (%)								
Usually received	52 (17,1%)	21 (17,9%)	23 (15,4%)	12 (19,4%)	18 (16,1%)	7 (16,7%)	11 (25,6%)	2 (15,4%)
Received in the last year	42 (13,8%)	12 (10,3%)	17 (11,4%)	5 (8,1%)	15 (13,4%)	5 (11,9%)	10 (23,3%)	2 (15,4%)

435 Notes:

436 1. Subset of participants who contracted COVID-19 had least once during the study period.

- 437 2. Comorbidities related to an increased risk of hospitalisation at the first visit.
- 438 3. 30.6% of participants had a BMI in the range of obesity, but only one reported to be obese.

## 439 **Table 5. Occupational and behavioral characteristic of study participants**

	Overa popu	II study Ilation	Restau wo	ırant/bar rkers	Groce	Grocery store workers		Hardware store workers	
	Total (N=304)	COVID-19 <sup>1</sup> (N=117)	Total (N=149)	COVID-19 <sup>1</sup> (N=62)	Total (N=112)	COVID-19 <sup>1</sup> (N=42)	Total (N=43)	COVID-19 <sup>1</sup> (N=13)	
Workplace region. <sup>2</sup> N (%)									
Capitale-Nationale	240 (78,9%)	96 (82,1%)	123 (82,6%)	49 (79,0%)	85 (75,9%)	36 (85,7%)	32 (74,4%)	11 (84,6%)	
Chaudière-Appalaches	64 (21,1%)	19 (16,2%)	26 (17,4%)	12 (19,4%)	27 (24,1%)	6 (14,3%)	11 (25,6%)	1 (7,7%)	
Weekly hours worked, <sup>3</sup> Mean±SD Participants working	<b>27,9</b> ± 11,5	28,9 ± 11,4	24,7 ± 11,0	24,5 ± 11,0	<b>32,6</b> ± 10,4	34,2 ± 9,8	<b>26,6</b> ± 11,9	32,3 ± 10,4	
Full time (≥30)	141 (46,4%)	64 (54,7%)	49 (32,9%)	23 (37,1%)	73 (65,2%)	32 (76,2%)	19 (44,2%)	9 (69,2%)	
Part time (<30)	163 (53,6%)	53 (45,3%)	100 (67,1%)	39 (62,9%)	39 (34,8%)	10 (23,8%)	24 (55,8%)	4 (30,8%)	
Gathering of 10+ persons, <sup>3</sup> Mean±SD Per group, N (%)	17,1 ± 27,5	<b>22,5</b> ± 31,4	<b>23,2</b> ± 33,9	31,5 ± 38,9	<b>10,4</b> ± 15,8	13,1 ± 15,9	13,7 ± 22,1	9,9 ± 10,4	
None	34 (11,2%)	6 (5,1%)	16 (10,7%)	2 (3,2%)	15 (13,4%)	4 (9,5%)	3 (7,0%)	0 (0,0%)	
1 to 10 gatherings	146 (48,0%)	47 (40,2%)	57 (38,3%)	16 (25,8%)	62 (55,4%)	22 (52,4%)	27 (62,8%)	9 (69,2%)	
11 to 50 gatherings	101 (33,2%)	51 (43,6%)	58 (38,9%)	33 (53,2%)	32 (28,6%)	14 (33,3%)	11 (25,6%)	4 (30,8%)	
>50 gatherings	23 (7,6%)	13 (11,1%)	18 (12,1%)	11 (17,7%)	3 (2,7%)	2 (4,8%)	2 (4,7%)	0 (0,0%)	
Transportation. <sup>2</sup> N (%)									
Car	266 (87,5%)	103 (88,0%)	127 (85,2%)	54 (87,1%)	98 (87,5%)	37 (88,1%)	41 (95,3%)	12 (92,3%)	
Carpooling	2 (0,7%)	2 (1,7%)	1 (0,7%)	1 (1,6%)	1 (0,9%)	1 (2,4%)	0 (0,0%)	0 (0,0%)	
Bus	39 (12,8%)	16 (13,7%)	23 (15,4%)	9 (14,5%)	10 (8,9%)	5 (11,9%)	6 (14,0%)	2 (15,4%)	
Bicycle	13 (4,3%)	6 (5,1%)	7 (4,7%)	3 (4,8%)	4 (3,6%)	2 (4,8%)	2 (4,7%)	1 (7,7%)	
Walking	28 (9,2%)	11 (9,4%)	13 (8,7%)	6 (9,7%)	14 (12,5%)	5 (11,9%)	1 (2,3%)	0 (0,0%)	
Travel, <sup>3</sup> N (%)									
Any destination	143 (47,0%)	70 (59,8%)	79 (53,0%)	40 (64,5%)	48 (42,9%)	25 (59,5%)	16 (37,2%)	5 (38,5%)	
In Canada	78 (25,7%)	39 (33,3%)	45 (30,2%)	24 (38,7%)	23 (20,5%)	<b>13</b> (31,0%)	10 (23,3%)	2 (15,4%)	
To USA	45 (14,8%)	20 (17,1%)	25 (16,8%)	11 (17,7%)	16 (14,3%)	8 (19,0%)	4 (9,3%)	1 (7,7%)	
Other destination <sup>4</sup>	84 (27,6%)	45 (38,5%)	47 (31,5%)	25 (40,3%)	28 (25,0%)	16 (38,1%)	9 (20,9%)	4 (30,8%)	

440 Notes:

1. Subset of participants who contracted COVID-19 had least once during the study period.

- 442 2. At the time of the first visit (i.e., week 0).
- 443 3. During the entire study period.
- 444 4. Includes travel to Cuba, Ireland, Great-Britain, Luxembourg, Dominican Republic, South Africa, Bahamas, Morocco, Guadeloupe,
- 445 Panama, Costa Rica, Greece.

### 447 Table 6. Protective measures taken at work and elsewhere by study participants at first visit

	Overall popul	study ation	Restaur work	ant/bar kers	Grocery store workers		Hardware store workers	
	Total (N=304)	COVID-19 <sup>1</sup> (N=117)	Total (N=149)	COVID-19 <sup>1</sup> (N=62)	Total (N=112)	COVID-19 <sup>1</sup> (N=42)	Total (N=43)	COVID-19 <sup>1</sup> (N=13)
Protection measures at work, <sup>2</sup> N (%)								
Mask	300 (98,7%)	116 (99,1%)	147 (98,7%)	61 (98,4%)	111 (99,1%)	42 (100,0%)	41 (95,3%)	13 (100,0%)
Handwashing	299 (98,4%)	114 (97,4%)	145 (97,3%)	59 (95,2%)	111 (99,1%)	42 (100,0%)	43 (100,0%)	13 (100,0%)
Plexiglas	235 (77,3%)	88 (75,2%)	96 (64,4%)	39 (62,9%)	98 (87,5%)	37 (88,1%)	41 (95,3%)	12 (92,3%)
Social distancing	213 (70,1%)	86 (73,5%)	111 (74,5%)	48 (77,4%)	74 (66,1%)	29 (69,0%)	28 (65,1%)	9 (69,2%)
Protective glasses	77 (25,3%)	12 (10,3%)	30 (20,1%)	4 (6,5%)	35 (31,3%)	5 (11,9%)	12 (27,9%)	3 (23,1%)
Faceshield	32 (10,5%)	4 (3,4%)	16 (10,7%)	1 (1,6%)	13 (11,6%)	2 (4,8%)	3 (7,0%)	1 (7,7%)
Gloves	21 (6,9%)	3 (2,6%)	10 (6,7%)	0 (0,0%)	9 (8,0%)	3 (7,1%)	2 (4,7%)	0 (0,0%)
Face Cover	7 (2,3%)	1 (0,9%)	3 (2,0%)	0 (0,0%)	4 (3,6%)	1 (2,4%)	0 -	0 (0,0%)
Other <sup>3</sup>	135 (44,4%)	59 (50,4%)	85 (57,0%)	41 (66,1%)	43 (38,4%)	16 (38,1%)	7 (16,3%)	2 (15,4%)
Behavioral protection measures, <sup>2</sup> N (%)								
Mask wearing in public spaces	304 (100,0%)	117 (100,0%)	149 (100,0%)	62 (100,0%)	112 (100,0%)	42 (100,0%)	43 (100,0%)	12 (92,3%)
Avoid usual salutations	259 (85,2%)	99 (84,6%)	119 (79,9%)	48 (77,4%)	103 (92,0%)	39 (92,9%)	37 (86,0%)	12 (92,3%)
Social distancing	256 (84,2%)	93 (79,5%)	115 (77,2%)	41 (66,1%)	102 (91,1%)	40 (95,2%)	39 (90,7%)	12 (92,3%)
Avoid contacts with vulnerable persons	254 (83,6%)	93 (79,5%)	114 (76,5%)	42 (67,7%)	100 (89,3%)	38 (90,5%)	40 (93,0%)	13 (100,0%)
Avoid crowded places	233 (76,6%)	81 (69,2%)	102 (68,5%)	35 (56,5%)	94 (83,9%)	34 (81,0%)	37 (86,0%)	12 (92,3%)
Quarantine if exposed to COVID-19	126 (41,4%)	70 (59,8%)	65 (43,6%)	36 (58,1%)	46 (41,1%)	25 (59,5%)	15 (34,9%)	9 (69,2%)
Pre-emptive isolation	36 (11,8%)	23 (19,7%)	21 (14,1%)	13 (21,0%)	12 (10,7%)	9 (21,4%)	3 (7,0%)	1 (7,7%)
Handwashing habits, <sup>2</sup> N (%)								
After using the toilet	297 (97,7%)	115 (98,3%)	147 (98,7%)	60 (96,8%)	109 (97,3%)	42 (100,0%)	41 (95,3%)	13 (100,0%)
When dirty	294 (96,7%)	113 (96,6%)	140 (94,0%)	58 (93,5%)	112 (100,0%)	42 (100,0%)	42 (97,7%)	13 (100,0%)
When entering workspace	280 (92,1%)	106 (90,6%)	136 (91,3%)	55 (88,7%)	107 (95,5%)	37 (88,1%)	37 (86,0%)	13 (100,0%)
Before eating	267 (87,8%)	104 (88,9%)	124 (83,2%)	51 (82,3%)	105 (93,8%)	41 (97,6%)	38 (88,4%)	12 (92,3%)
Before & after handling food	246 (80,9%)	96 (82,1%)	127 (85,2%)	55 (88,7%)	93 (83,0%)	32 (76,2%)	26 (60,5%)	9 (69,2%)
After handling trash	242 (79,6%)	97 (82,9%)	119 (79,9%)	51 (82,3%)	95 (84,8%)	38 (90,5%)	28 (65,1%)	8 (61,5%)
When exiting workspace	218 (71,7%)	81 (69,2%)	104 (69,8%)	41 (66,1%)	87 (77,7%)	32 (76,2%)	27 (62,8%)	8 (61,5%)
Other <sup>4</sup>	50 (16,4%)	11 (9,4%)	29 (19,5%)	4 (6,5%)	12 (10,7%)	2 (4,8%)	9 (20,9%)	5 (38,5%)

448 Notes:

1. Subset of participants who contracted COVID-19 had least once during the study period

- 450 2. Includes customer registry, QR code, customer limit in store, thorough cleaning of workplace, worker temperature surveillance.
- 451 3. Includes after touching the cash register, handling money, in between clients.

# 452 **Table 7. Number of COVID-19 positive tests**

	Overall cohort	Bar/ Restaurant	Grocery store	Hardware store
Reported positive COVID-19 tests				
First occurrence PCR Antigen detection	<b>117</b> 40 77	<b>62</b> 24 38	<b>42</b> 13 29	<b>13</b> 3 10
Additional test <sup>1</sup> PCR Antigen detection	<b>8</b> 1 7	<b>5</b> 1 4	<b>2</b> 0 2	<b>1</b> 0 1
Positive PCR test for COVID-19 at V4 or V5	11	6	5	0
First occurrence Additional test	4	1	3	0
≥90 days from previous test	3	2	1	0
Reported symptoms (no positive test)	31	17	12	2

453 Notes:

454 1. All 90 days or more since a previously positive test.

# **Table 8. COVID-19 symptoms at the first COVID-19 positive test reported by the participant**

	Overall cohort (N=117)	Bar/ Restaurant (N=62)	Grocery store (N=42)	Hardware store (N=13)
Asymptomatic infection, N (%)	6 (5,1%)	2 (3,2%)	4 (9,5%)	0 (0,0%)
Symptomatic infection, N (%)	111 (94,9%)	60 (96,8%)	38 (90,5%)	13 (100,0%)
Runny nose or nasal congestion	76 (65,0%)	39 (62,9%)	26 (61,9%)	11 (84,6%)
Cough	74 (63,2%)	41 (66,1%)	25 (59,5%)	8 (61,5%)
Headache	71 (60,7%)	36 (58,1%)	26 (61,9%)	9 (69,2%)
Sore throat	70 (59,8%)	41 (66,1%)	23 (54,8%)	6 (46,2%)
Fever	68 (58,1%)	39 (62,9%)	19 (45,2%)	9 (69,2%)
Muscle pain	65 (55,6%)	35 (56,5%)	22 (52,4%)	8 (61,5%)
Shortness of breath	56 (47,9%)	27 (43,5%)	21 (50,0%)	8 (61,5%)
Loss of sense of smell or taste	26 (22,2%)	11 (17,7%)	10 (23,8%)	5 (38,5%)
Diarrhea	16 (13,7%)	7 (11,3%)	8 (19,0%)	1 (7,7%)

# **Table 9. COVID-19 vaccination status at the first reported COVID-19 positive test**

	Overall cohort (N=117)	Bar/ Restaurant (N=62)	Grocery store (N=42)	Hardware store (N=13)
Vaccination status, N (%)				
No vaccine	21 (17.9%)	11 (17.7%)	10 (23.8%)	0 (0.0%)
One dose	1 (0.9%)	0 (0.0%)	1 (2.4%)	0 (0.0%)
Two doses	45 (38.5%)	24 (38.7%)	15 (35.7%)	6 (46.2%)
Three doses	46 (39.3%)	26 (41.9%)	14 (33.3%)	6 (46.2%)
Four doses	4 (3.4%)	1 (1.6%)	2 (4.8%)	1 (7.7%)

460	Table 10. Blood sam	ples collected by	vaccination status

	Overall cohort Blood samples (N = 1299)		
	Infected	Not infected	
No Vaccine, N (%)	11 (0.8%)	89 (6.9%)	
Vaccinated, N (%)	300 (23.1%)	899 (69.2%)	
1 dose	14 (1.1%)	61 (4.7%)	
2 doses	145 (11.2%)	584 (45.0%)	
3 doses	122 (9.4%)	231 (17.8%)	
4 doses	20 (1.5%)	22 (1.7%)	

### Figure 1. Timeline of the study illustrating the visits (colored dash lines) and the first occurrences of COVID-

## 19-positive tests (grey bars)



Figure 2. Evolution of the vaccination coverage (Comirnaty [Pfizer-BioNTech], SpikeVax [Moderna] or Vaxzevria [AstraZeneca] vaccine) during the study period (A) in the overall cohort stratified by the number of doses received, and (B) stratified by

occupational group. The study data are compared to those of the Public Health Agency of Canada (Qc population) for the whole

province.20

